Ignite Creation Date:
2025-12-24 @ 11:36 PM
Ignite Modification Date:
2025-12-25 @ 9:26 PM
Study NCT ID:
NCT04674956
Status:
RECRUITING
Last Update Posted:
2024-04-02
First Post:
2020-12-15
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer
Sponsor:
RenJi Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-03-04
Start Date Type:
ACTUAL
Primary Completion Date:
2024-12-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2020-12-15
First Submit QC Date:
None
Study First Post Date:
2020-12-19
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-03-31
Last Update Post Date:
2024-04-02
Last Update Post Date Type:
ACTUAL